U.S. Markets closed
  • S&P 500

    4,538.43
    -38.67 (-0.84%)
     
  • Dow 30

    34,580.08
    -59.71 (-0.17%)
     
  • Nasdaq

    15,085.47
    -295.85 (-1.92%)
     
  • Russell 2000

    2,159.31
    -47.02 (-2.13%)
     
  • Crude Oil

    66.22
    -0.28 (-0.42%)
     
  • Gold

    1,782.10
    +21.40 (+1.22%)
     
  • Silver

    22.57
    +0.25 (+1.12%)
     
  • EUR/USD

    1.1317
    +0.0012 (+0.1019%)
     
  • 10-Yr Bond

    1.3430
    -0.1050 (-7.25%)
     
  • Vix

    30.67
    +2.72 (+9.73%)
     
  • GBP/USD

    1.3235
    -0.0067 (-0.5029%)
     
  • USD/JPY

    112.8000
    -0.4090 (-0.3613%)
     
  • BTC-USD

    49,282.67
    -3,264.12 (-6.21%)
     
  • CMC Crypto 200

    1,367.14
    -74.62 (-5.18%)
     
  • FTSE 100

    7,122.32
    -6.89 (-0.10%)
     
  • Nikkei 225

    28,029.57
    +276.20 (+1.00%)
     

CASI Pharmaceuticals Announces Second Quarter 2021 Financial Results

  • Oops!
    Something went wrong.
    Please try again later.
·12 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

- EVOMELA Second Quarter 2021 Revenue Continues Upward Trend; Revenue Growth Guidance in 2021 Revised to Exceed 80% Over 2020 -

- CID-103 Reaches Milestone with Dosing of First Patient -

- Notice of Patent Allowance Issued in China for BI-1206 -

- Company to host Conference Call Today at 8:00 AM. ET -

ROCKVILLE, Md. and BEIJING, Aug. 12, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the second quarter of 2021.

CASI Pharmaceuticals logo (PRNewsFoto/CASI Pharmaceuticals, Inc.)
CASI Pharmaceuticals logo (PRNewsFoto/CASI Pharmaceuticals, Inc.)

Wei-Wu He, Ph.D., CASI's Chairman and Chief Executive Officer, commented, "We are pleased to report $7.1 million EVOMELA® revenues for the quarter. Based on the current trend, we are revising our guidance for full-year 2021 revenue growth to exceed 80% over 2020. We are proud of our commercial franchise execution for EVOMELA and have expanded to over 100 FTEs on the commercial and marketing teams. In addition to the continued EVOMELA revenue growth, we achieved dosing of first patient of CID-103 in our Phase 1 clinical trial for relapse or refectory multiple myeloma. CID-103 has previously shown encouraging preclinical efficacy, a favorable preclinical safety profile, and greater antibody-dependence cellular cytotoxicity activity over other anti-CD38 mAbs, and we are hopeful this will translate into patient benefit."

Dr. He continued, "We are thrilled with the progress we continue to see throughout our hematology oncology pipeline. Our partner, Juventas, has completed CNCT19's (CD19 CAR-T) Phase 1 studies of B-ALL and B-NHL in China. The Phase 2 B-NHL and B-ALL registration studies of CNCT19 are currently enrolling in China. Additionally, BioInvent recently announced that the China National Intellectual Property Administration (CNIPA) has issued a notice of allowance, informing the company that a patent application relating to the anti-FcγRllB antibody BI-1206 is expected to be granted. Together with BioInvent we plan to continue to develop BI-1206 in both hematological malignancies and solid tumors, with CASI responsible for development and commercialization in Greater China."

Second Quarter 2021 Financial Results

  • Revenues consist of product sales of EVOMELA that launched during August 2019. Revenue was $7.1 million for the three months ended June 30, 2021 compared to $2.6 million for the three months ended June 30, 2020. Revenues increased by 173% in the second quarter of 2021 as compared to same quarter in 2020 due to the continued growth in EVOMELA sales.

  • Costs of revenues were $2.9 million for the three months ended June 30, 2021, compared to $2.5 million for the three months ended June 30, 2020, which includes royalty payment of $1.4 million and $0.5 million for the same period. Costs of revenues excluding royalty were $1.5 million and $2.0 million for the three months ended June 30, 2021, and 2020. Costs of revenues, excluding royalty as a percentage of revenues, decreased significantly in the three months ended June 30, 2021, compared within the three months ended June 30, 2020, due to the new alternate manufacturer now in place, resulting in a considerable decrease in the unit cost of inventories of EVOMELA.

  • General and administrative expenses for the three months ended June 30, 2021 were $5.4 million, compared with $4.1 million for the three months ended June 30, 2020.

  • Selling and marketing expenses for the three months ended June 30, 2021 were $3.4 million, compared with $1.6 million for the three months ended June 30, 2020. The increase in selling and marketing expenses was due to expansion of sales team in China in 2021.

  • Acquired in-process R&D expenses for the three months ended June 30, 2021 was $1.06 million, compared to $0 million for the three months ended June 30, 2020. In June 2021, the Company achieved the First-Patient-In (FPI) in the Phase 1 dose escalation and expansion study of CID-103, and made $750,000 milestone payment and accrued €250,000 ($305,000) payment under the terms of the agreement.

  • Net loss for the three months ended June 30, 2021 was $6.7 million compared to $8.5 million for the three months ended June 30, 2020 due to significant revenue increase. As of June 30, 2021, CASI had cash and cash equivalents of $60.4 million compared to $57.1 million as of December 31, 2020.

Further information regarding the Company, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, can be found at www.casipharmaceuticals.com.

Conference Call

The Company will host a conference call reviewing the second quarter highlights today at 8:00 a.m. ET. The conference call can be accessed by dialing (833) 420-0382 (U.S.), (800) 870-0181 (China), (400) 682-8629 (China, domestic), 58086567 (Hong Kong) to listen to the live conference call. The conference ID number for the live call is 5639775. Participants dialing in via International Toll-Free Service (ITFS) numbers will be required to provide the following passcode to join the conference call: 8336474459, 6025859887.

This call will be recorded and available for replay by dialing (800) 859-2056 (U.S.) or (404) 537-3406 (international) and enter 5639775 to access the replay.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the greater China market leveraging the Company's China-based regulatory and commercial competencies and its global drug development expertise. The Company's operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd., which is located in Beijing, China. The Company has built a commercial team of more than 80 hematology and oncology sales and marketing specialists based in China. More information on CASI is available at www.casipharmaceuticals.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations, and goals. Forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including: the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the possibility that we may be delisted from trading on The Nasdaq Capital Market; the volatility in the market price of our common stock; the outbreak of the COVID-19 pandemic and its effects on global markets and supply chains; the risk of substantial dilution of existing stockholders in future stock issuances; the difficulty of executing our business strategy in China; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidates or future candidates; our lack of experience in manufacturing products and uncertainty about our resources and capabilities to do so on a clinical or commercial scale; risks relating to the commercialization, if any, of our products and proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks); our inability to predict when or if our product candidates will be approved for marketing by the U.S. Food and Drug Administration (FDA), National Medical Products Administration (NMPA), or other regulatory authorities; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidates or future candidates; the risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; the risks associated with our product candidates, and the risks associated with our other early-stage products under development; the risk that result in preclinical and clinical models are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; our ability to protect our intellectual property rights; our ability to design and implement a development plan for our ANDAs held by CASI Wuxi; the lack of success in the clinical development of any of our products; and our dependence on third parties; the risks related to our dependence on Juventas to conduct the clinical development of CNCT19 and to partner with us to co-market CNCT19; risks related to our dependence on Juventas to ensure the patent protection and prosecution for CNCT19; risks relating to the commercialization, if any, of our proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks); risks relating to interests of our largest stockholders and our Chairman and CEO that differ from our other stockholders; and risks related to the development of a new manufacturing facility by CASI Wuxi. Such factors, among others, could have a material adverse effect upon our business, results of operations, and financial condition. We caution readers not to place undue reliance on any forward-looking statements, which only speak as of the date made. Additional information about the factors and risks that could affect our business, financial condition, and results of operations, are contained in our filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.

EVOMELA® is proprietary to Acrotech Biopharma LLC and its affiliates..

COMPANY CONTACT:

CASI Pharmaceuticals, Inc.

240.864.2643

ir@casipharmaceuticals.com

INVESTOR CONTACT:

Bob Ai

Solebury Trout

646-389-6658

bai@soleburytrout.com

(Financial Table Follows)

CASI Pharmaceuticals, Inc.

Unaudited Condensed Consolidated Balance Sheets

(In thousands, except share and per share data)











June 30, 2021


December 31, 2020


ASSETS








Current assets:








Cash and cash equivalents


$

60,357


$

57,064


Investment in equity securities, at fair value



12,588



9,309


Accounts receivable, net of $0 allowance for doubtful accounts



5,767



4,645


Inventories



3,475



1,356


Prepaid expenses and other



1,318



1,651


Total current assets



83,505



74,025










Property, plant and equipment, net



3,348



2,062


Intangible assets, net



12,691



13,210


Long-term investments



34,679



29,442


Right of use assets



9,797



8,696


Other assets



506



299


Total assets


$

144,526


$

127,734










LIABILITIES, REDEEMABLE NONCONTROLLING INTEREST AND STOCKHOLDERS' EQUITY








Current liabilities:








Accounts payable


$

5,519


$

3,669


Accrued and other current liabilities



2,488



3,015


Bank borrowings



1,548



826


Notes payable



466



466


Total current liabilities



10,021



7,976










Deferred income



2,354



2,351


Other liabilities



14,654



13,834


Total liabilities



27,029



24,161










Commitments and contingencies (Note 18)
















Redeemable noncontrolling interest, at redemption value (Note 11)



22,697



22,033










Stockholders' equity:








Preferred stock, $1.00 par value: 5,000,000 shares authorized and 0 shares issued and






outstanding








Common stock, $0.01 par value:








250,000,000 shares authorized at June 30, 2021 and December 31, 2020








139,877,032 shares and 124,023,374 shares issued at June 30, 2021 and December 31, 2020, respectively;








139,797,487 shares and 123,943,829 shares outstanding at June 30, 2021 and December 31, 2020, respectively



1,399



1,240


Additional paid-in capital



690,539



658,246


Treasury stock, at cost: 79,545 shares held at June 30, 2021 and December 31, 2020



(8,034)



(8,034)


Accumulated other comprehensive income



1,159



589


Accumulated deficit



(590,263)



(570,501)


Total stockholders' equity



94,800



81,540


Total liabilities, redeemable noncontrolling interest and stockholders' equity


$

144,526


$

127,734


CASI Pharmaceuticals, Inc.

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share data)

















Three Months Ended June 30


Six Months Ended June 30




2021


2020


2021


2020


Revenues:














Product sales


$

7,125


$

2,638


$

12,825


$

6,010


Lease income



37



33



73



67


Total revenues



7,162



2,671



12,898



6,077
















Costs and expenses:














Costs of revenues



2,982



2,517



5,340



5,728


Research and development



2,255



1,862



7,513



4,879


General and administrative



5,423



4,085



10,925



8,143


Selling and marketing



3,360



1,557



6,075



2,817


Loss on disposal of property, plant, equipment



65





65




Gain on disposal of intangible assets









(450)


Impairment of intangible assets





1,537





1,537


Acquired in-process research and development



1,055





6,555



1,081


Total costs and expenses



15,140



11,558



36,473



23,735
















Loss from operations



(7,978)



(8,887)



(23,575)



(17,658)


Non-operating income/(expense):














Interest income, net



76



153



182



343


Other income



33



27



53



27


Foreign exchange gains (losses)



76



(115)



295



248


Change in fair value of investments



1,914



324



3,482



309


Impairment loss of long-term investments



(865)





(865)




Net loss



(6,744)



(8,498)



(20,428)



(16,731)


Less: loss attributable to redeemable noncontrolling interest



(317)



(166)



(666)



(275)


Accretion to redeemable noncontrolling interest redemption value



519



362



1,067



679


Net loss attributable to CASI Pharmaceuticals, Inc.


$

(6,946)


$

(8,694)


$

(20,829)


$

(17,135)
















Net loss per share (basic and diluted)


$

(0.05)


$

(0.09)


$

(0.16)


$

(0.17)


Weighted average number of common shares outstanding (basic and diluted)



139,797,487



100,921,137



132,352,399



99,847,186
















Comprehensive loss:














Net loss


$

(6,744)


$

(8,498)


$

(20,428)


$

(16,731)


Foreign currency translation adjustment



1,005



(336)



833



(1,162)


Total comprehensive loss


$

(5,739)


$

(8,834)


$

(19,595)


$

(17,893)


Less: Comprehensive loss attributable to redeemable noncontrolling interest



14



(166)



(403)



(275)


Comprehensive loss attributable to common stockholders


$

(5,753)


$

(8,668)


$

(19,192)


$

(17,618)


Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/casi-pharmaceuticals-announces-second-quarter-2021-financial-results-301354137.html

SOURCE CASI Pharmaceuticals, Inc.